Findings

What do systematic reviews say?

86 questions · 86 findings · 29 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 51 · 59.3%GRADE not reported 1 · 1.2%Very low 8 · 9.3%Low 16 · 18.6%Moderate 8 · 9.3%High 2 · 2.3%

Radioembolisation plus sorafenib vs sorafenib monotherapy

Health‐related quality of life · people with hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Radioembolisation vs sorafenib monotherapy

Health‐related quality of life · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 360 participants
Very low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 506 participants
Low

Sunitinib vs everolimus (targeted agent versus targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 288 participants
Low

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 691 participants
Low

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 544 participants
Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 401 participants
Low

Sunitinib vs atezolizumab (targeted therapy versus immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 394 participants
Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 460 participants
Moderate

Pazopanib vs placebo (targeted agent versus placebo)

Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 300 participants
High

TACE followed by 3‐DCRT vs chemoembolisation

Health‐related quality of life · primary hepatocellular carcinoma

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Very low

Gemcitabine plus cisplatin vs S‐1 plus cisplatin

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus S‐1 vs S‐1

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs best supportive care

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus vandetanib vs vandetanib

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

Health‐related quality of life · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

External beam radiotherapy for unresectable hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Percutaneous ethanol injection vs radiofrequency ablation

Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

The review found no eligible studies for this question.

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found